A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...

Melanoma is the deadliest form of skin cancer. A new vaccine-drug combo could slash recurring cases - An estimated 112,000 ...

The approvals are based on a Phase 3 study that showed the Keytruda-Welireg combo cut the risk of the cancer coming back, spreading or death by 28% compared with Keytruda plus pla ...

Research done right here in Nashville shows a new approach is leading to promising results in the fight against melanoma, ...

A subcutaneous (SC) immune anticancer drug that can be administered in 1–2 minutes by injection under the skin has been newly ...

May 21 (Reuters) - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a ...

Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.